척추 생물제제 시장, 점유율, 규모, 동향, 산업 분석 보고서 : 제품별, 최종 사용자별, 지역별, 부문별 예측(2024-2032년)

The global spine biologics market size is expected to reach USD 3.16 billion by 2032, according to a new study by Polaris Market Research. The report "Spine Biologics Market Share, Size, Trends, Industry Analysis Report, By Product (Bone Graft Substitutes, Spinal Allografts, Others); By End User; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The spine biologics market is driven by increasing global healthcare expenditure. With more resources allocated to treating spinal disorders like degenerative disc disease and spinal fractures, demand for innovative treatments such as spine biologics is rising. Higher healthcare spending enables greater investment in research, leading to advanced biologic products tailored for spinal applications like bone graft substitutes and stem cell therapies. Additionally, increased expenditure supports enhanced access to diagnostic technologies like MRI and CT scans, facilitating early detection and treatment. Adoption of minimally invasive surgical techniques, coupled with spine biologics, offers patients less invasive alternatives to traditional surgeries, driving market growth while contributing to cost savings.

The spine biologics market is also growing due to expanding applications in spine fusion procedures, commonly performed for degenerative disc disease and spinal fractures. Biologic products promote bone growth and enhance spinal stability, facilitating successful fusion. Advancements in biotechnology have led to innovative spine biologics, offering solutions for complex spinal conditions. These products stimulate bone regeneration, improving patient outcomes and reducing the need for additional interventions. With an aging population and increasing prevalence of degenerative spine conditions, demand for spine biologics is rising. Surgeons are integrating biologic products into treatment protocols to meet patient expectations for better outcomes. Regulatory approvals for biologic treatments in spinal applications further support market expansion, driving growth in the spine biologics market.

Personalized medicine approaches tailor treatments based on genetic makeup, lifestyle, and disease characteristics. Advanced genetic testing and biomarker analysis enable clinicians to select the most suitable biologic therapies for each patient, optimizing efficacy and minimizing side effects. Additionally, personalized medicine fosters the development of novel biologic treatments, including gene therapies and precision-targeted biologics, customized to specific patient subgroups. This collaborative effort between healthcare providers, researchers, and biotech firms drives innovation in spine biologics, offering more effective and patient-centric treatments.

Emerging markets are fostering opportunities in the spine biologics market owing to rapid economic growth and healthcare infrastructure development. In regions like Asia-Pacific, Latin America, and the Middle East, rising demand for advanced medical treatments accompanies the increasing prevalence of spinal disorders due to aging populations and urbanization. Heightened healthcare expenditure enables investment in innovative technologies, including spine biologics. Collaborations between multinational corporations and local healthcare providers facilitate product introduction and adoption. These partnerships drive knowledge exchange and localized development to meet the evolving healthcare needs of emerging markets.

Spine Biologics Market Report Highlights

In 2023, the spinal allografts segment held a significant revenue share owing to clinical acceptance, proven efficacy, and minimal disease transmission risk.

In 2023, the hospitals and clinics segment held a significant revenue share owing to comprehensive care services, advanced infrastructure, and experienced healthcare professionals.

In 2023, the North America region accounted for a significant market share due to advanced healthcare infrastructure, high prevalence of spinal disorders, and well-established regulatory framework.

The market is highly competitive owing to the existence of market players with a global presence, including Arthrex, Inc., Johnson & Johnson, Medtronic plc, NuVasive, Inc., Organogenesis Inc., Orthofix Medical Inc., Stryker Corporation, and Zimmer Biomet Holdings, Inc. among others.

Polaris Market Research has segmented the Spine Biologics market report based on product, end user, and region:

Spine Biologics, Product Outlook (Revenue - USD Billion, 2019 - 2032)

• Bone Graft Substitutes
• Spinal Allografts
• Others

Spine Biologics, End User Channel Outlook (Revenue - USD Billion, 2019 - 2032)

• Hospitals and Clinics
• Ambulatory Surgical Centers
• Others

Spine Biologics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America
• U.S.
• Canada
• Europe
• France
• Germany
• UK
• Italy
• Netherlands
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• Japan
• China
• India
• Malaysia
• Indonesia
• South Korea
• Australia
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• UAE
• Israel
• South Africa
• Rest of Middle East & Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Spine Biologics Market Insights

• 4.1. Spine Biologics Market - Industry Snapshot
• 4.2. Spine Biologics Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increasing incidence of spinal disorders is projected to spur the product demand
    • 4.2.1.2. Growing preference for minimally invasive procedures is expected to drive spine biologics market growth
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. High cost of treatment is likely to impede the market growth
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTLE Analysis
• 4.5. Spine Biologics Industry trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Spine Biologics Market, by Product

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Spine Biologics, by Product, 2019-2032 (USD Billion)
• 5.3. Bone Graft Substitutes
  • 5.3.1. Global Spine Biologics Market, by Bone Graft Substitutes, by Region, 2019-2032 (USD Billion)
• 5.4. Spinal Allografts
  • 5.4.1. Global Spine Biologics Market, by Spinal Allografts, by Region, 2019-2032 (USD Billion)
• 5.5. Others
  • 5.5.1. Global Spine Biologics Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Spine Biologics Market, by End User

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Spine Biologics Market, by End User, 2019-2032 (USD Billion)
• 6.3. Hospitals and Clinics
  • 6.3.1. Global Spine Biologics Market, by Hospitals and Clinics, by Region, 2019-2032 (USD Billion)
• 6.4. Ambulatory Surgical Centers
  • 6.4.1. Global Spine Biologics Market, by Ambulatory Surgical Centers, by Region, 2019-2032 (USD Billion)
• 6.5. Others
  • 6.5.1. Global Spine Biologics Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Spine Biologics Market, by Geography

• 7.1. Key findings
• 7.2. Introduction
  • 7.2.1. Spine Biologics Market Assessment, By Geography, 2019-2032 (USD Billion)
• 7.3. Spine Biologics Market - North America
  • 7.3.1. North America: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • 7.3.2. North America: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.3.3. Spine Biologics Market - U.S.
    • 7.3.3.1. U.S.: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.3.3.2. U.S.: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.3.4. Spine Biologics Market - Canada
    • 7.3.4.1. Canada: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.3.4.2. Canada: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
• 7.4. Spine Biologics Market - Europe
  • 7.4.1. Europe: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • 7.4.2. Europe: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.4.3. Spine Biologics Market - UK
    • 7.4.3.1. UK: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.4.3.2. UK: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.4.4. Spine Biologics Market - France
    • 7.4.4.1. France: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.4.4.2. France: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.4.5. Spine Biologics Market - Germany
    • 7.4.5.1. Germany: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.4.5.2. Germany: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.4.6. Spine Biologics Market - Italy
    • 7.4.6.1. Italy: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.4.6.2. Italy: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.4.7. Spine Biologics Market - Spain
    • 7.4.7.1. Spain: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.4.7.2. Spain: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.4.8. Spine Biologics Market - Netherlands
    • 7.4.8.1. Netherlands: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.4.8.2. Netherlands: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.4.9. Spine Biologics Market - Russia
    • 7.4.9.1. Russia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.4.9.2. Russia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
• 7.5. Spine Biologics Market - Asia Pacific
  • 7.5.1. Asia Pacific: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • 7.5.2. Asia Pacific: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.5.3. Spine Biologics Market - China
    • 7.5.3.1. China: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.5.3.2. China: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.5.4. Spine Biologics Market - India
    • 7.5.4.1. India: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.5.4.2. India: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.5.5. Spine Biologics Market - Malaysia
    • 7.5.5.1. Malaysia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.5.5.2. Malaysia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.5.6. Spine Biologics Market - Japan
    • 7.5.6.1. Japan: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.5.6.2. Japan: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.5.7. Spine Biologics Market - Indonesia
    • 7.5.7.1. Indonesia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.5.7.2. Indonesia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.5.8. Spine Biologics Market - South Korea
    • 7.5.8.1. South Korea: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.5.8.2. South Korea: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
• 7.6. Spine Biologics Market - Middle East & Africa
  • 7.6.1. Middle East & Africa: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • 7.6.2. Middle East & Africa: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.6.3. Spine Biologics Market - Saudi Arabia
    • 7.6.3.1. Saudi Arabia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.6.3.2. Saudi Arabia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.6.4. Spine Biologics Market - UAE
    • 7.6.4.1. UAE: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.6.4.2. UAE: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.6.5. Spine Biologics Market - Israel
    • 7.6.5.1. Israel: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.6.5.2. Israel: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.6.6. Spine Biologics Market - South Africa
    • 7.6.6.1. South Africa: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.6.6.2. South Africa: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
• 7.7. Spine Biologics Market - Latin America
  • 7.7.1. Latin America: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • 7.7.2. Latin America: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.7.3. Spine Biologics Market - Mexico
    • 7.7.3.1. Mexico: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.7.3.2. Mexico: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.7.4. Spine Biologics Market - Brazil
    • 7.7.4.1. Brazil: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.7.4.2. Brazil: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.7.5. Spine Biologics Market - Argentina
    • 7.7.5.1. Argentina: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.7.5.2. Argentina: Spine Biologics Market, by Product, 2019-2032 (USD Billion)

8. Competitive Landscape

• 8.1. Expansion and Acquisition Analysis
  • 8.1.1. Expansion
  • 8.1.2. Acquisitions
• 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

• 9.1. Arthrex, Inc
  • 9.1.1. Company Overview
  • 9.1.2. Financial Performance
  • 9.1.3. Product Benchmarking
  • 9.1.4. Recent Development
• 9.2. Baxter International Inc.
  • 9.2.1. Company Overview
  • 9.2.2. Financial Performance
  • 9.2.3. Product Benchmarking
  • 9.2.4. Recent Development
• 9.3. Exactech, Inc.
  • 9.3.1. Company Overview
  • 9.3.2. Financial Performance
  • 9.3.3. Product Benchmarking
  • 9.3.4. Recent Development
• 9.4. Globus Medical Inc.
  • 9.4.1. Company Overview
  • 9.4.2. Financial Performance
  • 9.4.3. Product Benchmarking
  • 9.4.4. Recent Development
• 9.5. Johnson & Johnson (DePuy Synthes)
  • 9.5.1. Company Overview
  • 9.5.2. Financial Performance
  • 9.5.3. Product Benchmarking
  • 9.5.4. Recent Development
• 9.6. Kuros Biosciences
  • 9.6.1. Company Overview
  • 9.6.2. Financial Performance
  • 9.6.3. Product Benchmarking
  • 9.6.4. Recent Development
• 9.7. Medtronic plc
  • 9.7.1. Company Overview
  • 9.7.2. Financial Performance
  • 9.7.3. Product Benchmarking
  • 9.7.4. Recent Development
• 9.8. NuVasive, Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Financial Performance
  • 9.8.3. Product Benchmarking
  • 9.8.4. Recent Development
• 9.9. Organogenesis Inc.
  • 9.9.1. Company Overview
  • 9.9.2. Financial Performance
  • 9.9.3. Product Benchmarking
  • 9.9.4. Recent Development
• 9.10. Orthofix Medical Inc.
  • 9.10.1. Company Overview
  • 9.10.2. Financial Performance
  • 9.10.3. Product Benchmarking
  • 9.10.4. Recent Development
• 9.11. RTI Surgical Holdings, Inc.
  • 9.11.1. Company Overview
  • 9.11.2. Financial Performance
  • 9.11.3. Product Benchmarking
  • 9.11.4. Recent Development
• 9.12. SeaSpine Holdings Corporation
  • 9.12.1. Company Overview
  • 9.12.2. Financial Performance
  • 9.12.3. Product Benchmarking
  • 9.12.4. Recent Development
• 9.13. Spine Wave, Inc.
  • 9.13.1. Company Overview
  • 9.13.2. Financial Performance
  • 9.13.3. Product Benchmarking
  • 9.13.4. Recent Development
• 9.14. Stryker Corporation
  • 9.14.1. Company Overview
  • 9.14.2. Financial Performance
  • 9.14.3. Product Benchmarking
  • 9.14.4. Recent Development
• 9.15. Zimmer Biomet Holdings, Inc.
  • 9.15.1. Company Overview
  • 9.15.2. Financial Performance
  • 9.15.3. Product Benchmarking
  • 9.15.4. Recent Development